TGFB1 Protein (AA 30-278)

N° du produit ABIN7319851

Cette protéine Recombinant TGFB1 est produite dans HEK-293 Cells.

Aperçu rapide pour TGFB1 Protein (AA 30-278) (ABIN7319851)

Antigène: TGFB1 (Transforming Growth Factor, beta 1 (TGFB1))

Type de proteíne: Recombinant

Origine: Humain

Source: HEK-293 Cells

Pureté: > 95 % as determined by reducing SDS-PAGE.

Détail du produit

Attributs du protein: AA 30-278

Fonction: Recombinant Human Transforming Growth Factor Beta-1/TGFB1

Séquence: Leu30-Arg278(Cys33Ser)

Attributs du produit: Recombinant Human Transforming Growth Factor beta 1 is produced by our Mammalian expression system and the target gene encoding Leu30-Arg278(Cys33Ser) is expressed.

Stérilité: 0.2 μm filtered

niveau d'endotoxine: < 1.0 EU per μg of the protein as determined by the LAL method.

Biological Activity Comment: Not validated for activity

Information d'application

Restrictions: For Research Use only

Stockage

Format: Lyophilized

Buffer: Lyophilized from a 0.2 μm filtered solution of PBS, pH 7.4.
Normally 5 % - 8 % trehalose, mannitol and 0.01 % Tween 80 are added as protectants before lyophilization.

Stock: 4 °C,-20 °C,-80 °C

Stockage commentaire: Generally, lyophilized proteins are stable for up to 12 months when stored at -20 to -80°C. Reconstituted protein solution can be stored at 4-8°C for 2-7 days. Aliquots of reconstituted samples are stable at < -20°C for 3 months.

Date de péremption: 12 months

Détail du antigène

Antigène: TGFB1 (Transforming Growth Factor, beta 1 (TGFB1))

Autre désignation: Transforming Growth Factor Beta-1/TGFB1

Sujet: LAP,Latency-Associated Peptide,TGF-Beta-1,TGFB,TGFB1,Transforming Growth Factor Beta-1,Transforming Growth Factor β-1 (TGFβ-1) is a secreted protein which belongs to the TGF-β family. TGFβ-1 is abundantly expressed in bone, articular cartilage and chondrocytes and is increased in osteoarthritis (OA). TGFβ-1 performs many cellular functions, including the control of cell growth, cell proliferation, cell differentiation and apoptosis. The precursor is cleaved into a latency-associated peptide (LAP) and a mature TGFβ-1 peptide.Disulfide-linked homodimers of LAP and TGF-beta 1 remain non-covalently associated after secretion, forming the small latent TGF-beta 1 complex. Purified LAP is also capable of associating with active TGF-beta with high affinity, and can neutralize TGF-beta activity. Covalent linkage of LAP to one of three latent TGF-beta binding proteins (LTBPs) creates a large latent complex that may interact with the extracellular matrix. TGF-beta activation from latency is controlled both spatially and temporally, by multiple pathways that include actions of proteases such as plasmin and MMP9, and/or by thrombospondin 1 or selected integrins. Although different isoforms of TGF-beta are naturally associated with their own distinct LAPs, the TGF-beta 1 LAP is capable of complexing with, and inactivating, all other human TGF-beta isoforms and those of most other species. Mutations within the LAP are associated with Camurati-Engelmann disease, a rare sclerosing bone dysplasia characterized by inappropriate presence of active TGF-beta 1.

Poids moléculaire:

Calculated MW: 28.5 kDa

Observed MW: 20-30 kDa

ID gène: 7040

UniProt: P01137

Pathways: EGFR Signaling Pathway, Dopaminergic Neurogenesis, Cellular Response to Molecule of Bacterial Origin, Glycosaminoglycan Metabolic Process, Regulation of Leukocyte Mediated Immunity, Regulation of Muscle Cell Differentiation, Positive Regulation of Immune Effector Process, Cell-Cell Junction Organization, Production of Molecular Mediator of Immune Response, Ribonucleoside Biosynthetic Process, Skeletal Muscle Fiber Development, Regulation of Carbohydrate Metabolic Process, Protein targeting to Nucleus, Autophagy, Cancer Immune Checkpoints